HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering

The reduced-affinity strategy represents a promising framework for the clinical development of OX40-targeted cancer immunotherapies. Currently, HFB301001 is concluding in a phase I clinical study involving patients with advanced solid tumors (NCT05229601).